Study S001041

Improving Beta Cell Function in Mexican American Women With Prediabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02488057
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 360
Start: 2016-05
Primary completion: 2019-03
Lead sponsor: Ohio State University
Conditions: Pre-Diabetes
Interventions: DRUG:Liraglutide; BEHAVIORAL:Weight loss
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Beta Cell Function [3 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022988	Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Mari A, Diabetes care	2007	Randomized trial	PMID 17468345 DOI	registry reference BACKGROUND:17468345
R0026486	One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Degn KB, Diabetes	2004	Randomized trial	PMID 15111485 DOI	registry reference BACKGROUND:15111485